BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
23
Data completeness
4/8 — Partial
Priority Review
ZYNLONTA (loncastuximab tesirine) by ADC Therapeutics. Approved for diffuse large b-cell lymphoma. First approved in 2021.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNLONTA (loncastuximab tesirine) is an antibody-drug conjugate (ADC) that targets CD19-positive B-cell malignancies. It is approved for multiple relapsed or refractory B-cell lymphomas and leukemias, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The drug delivers a cytotoxic payload directly to cancer cells expressing the CD19 antigen.
$675KPart D
PeakEarly-stage commercial trajectory with modest Part D claims suggests team scaling opportunity as market adoption grows in hematologic malignancies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (23)
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Started Jan 2026
26 enrolled
Large B-cell LymphomaRelapse
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Started Oct 2025
120 enrolled
Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3B
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Started Aug 2025
29 enrolled
Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Started Mar 2025
12 enrolled
Central Nervous System Lymphoma
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Started May 2024
210 enrolled
B-cell Non Hodgkin Lymphoma
Worked on ZYNLONTA at ADC Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.